ROYAL SOCIETY
OF CHEMISTRY

PAPER

Check for updates

Synthesis of tricyclic carbohydrate–benzene hybrids as selective inhibitors of galectin-1 and galectin-8 N-terminal domains†

Chunxia Wu,[a] Can Yong,[a] Qiuju Zhong,[a] Zhouyu Wang, [ID][a] Ulf J. Nilsson [ID][b] and Yuanyuan Zhang [ID] *[a]

As the galactoside binding family of galectin proteins is involved in many physiological and pathological processes, the inhibitors of these proteins are considered to be of significant interest in the treatment of diseases such as cancer and fibrosis. Herein, fused tricyclic carbohydrate–benzene hybrid core structures are reported to be the selective inhibitors of galectin-1 and the N-terminal domain of galectin-8 by a competitive fluorescence polarization assay. The key intermediates mono- or diiodo tricyclic carbohydrate–benzene hybrids were synthesized from protected 2-bromo-3-*O*-propargyl-D-galactose *via* a domino reaction and subsequently utilized for further derivatization by Stille couplings to achieve derivatives carrying substituents at C10 and/or C11. Several compounds showed affinity for the galectin-1 and galectin-8 N-terminal (8N) domains; however, weak or even no binding was observed for galectin-3. Monosubstituted derivatives at C10 or C11 exhibited better affinity for galectin-8N than di-substituted derivatives at C10 or C11. Especially, a benzyl substituent or *p*-fluorobenzyl substituent at C11 displayed affinity and selectivity for galectin-1 and galectin-8N over galectin-3. This suggests that tricyclic carbohydrate–benzene hybrids are promising scaffolds for the development of selective galectin-1 and galectin-8N inhibitors.

1   Introduction

Galectins are glycan-binding proteins that selectively bind to glycoconjugates containing β-D-galactopyranoside residues. To date, more than 15 members of the galectin family have been identified, purified, isolated, and characterized, out of which, only 12 are found in humans.[1,2] These galectins are involved in many biological functions such as cell–cell[3] and cell–matrix interactions,[4] immune and inflammatory responses,[5,6] anti-apoptosis,[7] induction of T cell apoptosis, and regulation of cell adhesion and migration.[8] Among them, galectin-1 is widely expressed in the human body and is associated with various neurological diseases,[9] HIV-1 viral infectivity,[10] and cancer progression.[11] Moreover, galectin-1 has been highlighted as a diagnostic tumor marker.[12] In addition to this, galectin-8 has attracted attention due to its physiological activity. For example, it has been evidenced to regulate autophagy[13] and lymphangiogenesis[14] and is highly expressed in many clinical diseases such as larynx cancer, prostate cancer, breast cancer,

and cutaneous T cell lymphomas.[15–19] As a result, due to their intimate connection with diseases, galectins have become promising drug targets.

A variety of artificial galectin inhibitors have been synthesized in the past two decades. The structure of the inhibitors were typically based on monosaccharides or oligosaccharides,[20] such as D-galactose,[21,22] talose,[23] lactosamine,[24] and thio-digalactoside,[25,26] and with modifications mostly at C1 and C3 positions of galactoside. Both 4-OH and 6-OH were always conserved as they were essential for galectin binding. A majority of these inhibitors exhibit good affinity for galectin-3,[25–28] whereas fewer show potent affinity for other galectins such as **1** shows potent affinity for galectin-1 (ref. 27) and **2** shows potent affinity for galectin-8N[21] (Fig. 1). However, they all show similar or even more potent affinity for galectin-3. This drawback limits the application of the abovementioned compounds as galectin-1 or galectin-8 inhibitors in biological assays or systems.

[a]School of Science, Xihua University, Jinniu District, 610039 Chengdu, China. E-mail: yuanyuan.zhang@mail.xhu.edu.cn

[b]Centre for Analysis and Synthesis, Department of Chemistry, Lund University, POB 124, SE-221 00 Lund, Sweden

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra03144e

Fig. 1   Structures of the compound **1** and **2**.

Herein, a series of tricyclic carbohydrate–benzene hybrids was designed and synthesized. The key galectin-binding sites 4-OH and 6-OH of galactose were preserved, and C1–C3 were constrained by two rings to a fused and rigid tricyclic structure as previously reported by Werz et al.[29] This ring structure was hypothesized to favorably change the hydrophobic/hydrophilic properties of the inhibitors and enable the incorporation of substituents into them to optimize their affinity and selectivity for selected individual galectins among the panel of galectin-1,3,4 N-terminal (4N), 4 C-terminal (4C), 8N, 9 N-terminal (9N), and 9 C-terminal (9C) evaluated in the study.

2 Results and discussions

2.1 Chemistry

The tricyclic carbohydrate–benzene hybrids were synthesized by three strategies (Scheme 1).

At first, the tricyclic carbohydrate–benzene hybrids **8a–c** were acquired by the Pd-catalyzed domino reaction of **3** with different alkynes and subsequent deprotection using the method reported by Werz.[29] Subsequently, the benzylidene-protected di-trimethylsilyl tricyclic carbohydrate–benzene hybrid **7c** was converted to the diiodo-hybrid **4** by iodine monochloride. The benzylidene removal of **4** led to **5**, which was converted to the compounds **8d** and **8e** via palladium-catalyzed Stille couplings using organotins. Herein, four tricyclic carbohydrate–benzene hybrids having same substituents at both C10 and C11 and one compound with the mono-trimethylsilyl group were synthesized. Finally, the deprotected mono-trimethylsilyl-substituted tricyclic carbohydrate–benzene hybrid **8c** was utilized to prepare the mono-substituted hybrid molecules **9a–9d** through the monoiodo-hybrid intermediate **6** by similar Stille cross-couplings as the third strategy.

Scheme 1 Synthesis of tricyclic carbohydrate–benzene hybrids. Reagents and conditions: (a) substituted alkynes, Pd(PPh₃)₄, diisopropylamine, [(t-Bu)₃PH]BF₄, DMF/MeCN/NMP, and 100 °C; (b) 0.2 M HCl, MeOH, and 55 °C; (c) iodine monochloride, DCM, and r.t.; (d) 0.2 M HCl, MeOH, and 55 °C; (e) substituted tributyl stannane, triethylamine, CuI, Pd(PPh₃)₄, DMF, and 75 °C; (f) iodine monochloride, DCM, and r.t.; and (g) substituted tributyl stannane, triethylamine, CuI, Pd(PPh₃)₄, DMF, and 95 °C.

2.2 Galectin binding

The binding activities of the compounds **8a–e, 9a–d, 5,** and **6** for galectins were tested using a previously described competitive fluorescence polarization assay.[30,31] The data of these compounds and three reference ligands, i.e. methyl β-D-galactoside **10**, 1,1′-sulfanediyl-bis-{{3-deoxy-3-[4-(thiazol-2-yl)-1H-1,2,3-triazol-1-yl]-β-D-galactopyranoside}} **1**, and 3,4-dichlorophenyl 3-O-(7-carboxy-quinolin-2-yl-methyl)-1-thio-α-D-galactopyranoside **2**, are provided hereinafter.

A majority of the synthesized compounds exhibited obvious affinities for galectin-1 and galectin-8N, but no or very weak affinity for galectin-3. Hence, the selectivity of the tricyclic carbohydrate–benzene hybrids was significantly improved for galectin-1 and galectin-8N over galectin-3, which is rare among the reported inhibitors. Although the compound **1** is the best reported synthetic galectin-1 inhibitor to date, its affinity for galectin-3 was even more potent, which was 10-fold when compared with that for galectin-1. The compound **2** has been reported to be the most potent inhibitor for galectin-8N; however, it has a similar affinity for galectin-3. Compared with the case of the reference methyl β-galactoside **10**, the affinities of most of the tricyclic compounds were increased by 3–35 folds and more than 3–71 folds for galectin-8N and galectin-1, respectively, whereas most of the tested compounds exhibited weak or even no affinity for galectin-4C, 4N, 9C, or 9N (Table 1).

Structure–affinity analysis revealed that the substituents at the C10 and C11 positions of the tricyclic carbohydrate–benzene hybrids play a key role in the affinity of these hybrids for galectins. In general, the mono-substituted derivatives **6, 8c,** and **9a–9d** showed better galectin-8N binding than the di-substituted compounds **5, 8a, 8b, 8d,** and **8e**. The affinities of the disubstituted derivatives carrying aliphatic alkyl groups, such as ethyl (**8a**), n-propyl (**8b**), or propynyl (**8d**), for galectin-8N were very weak or could hardly be observed, whereas the affinities of those carrying di-benzyl groups (**8e**) and di-iodo (**5**) were increased to around 1500 and 2100 μM, respectively, which was more than 3 times that of the reference galactoside **10**. The analysis of the mono-substituted **8c, 9a, 9b, 9c, 9d,** and **6** revealed no binding of these derivatives to galectin-3, whereas their affinity for galectin-8N was changed. Compared to the best inhibitor 10,11-disubstituted **8e**, all the mono-substituted **8c, 9a, 9b, 9c, 9d,** and **6** showed improved affinity for galectin-8N. Similar to di-substituted derivatives, the benzyl derivative **9b** exhibited the best affinity for galectin-8N, along with the mono-iodo derivative **6**. The evaluation of the derivatives with substituted benzyl groups, i.e. p-methoxybenzyl **9c** and p-fluorobenzyl **9d**, revealed that the electron-donating group 4-methoxybenzyl at C10 (**9c**) decreased the affinity; thus, the affinity of **9c** was the worst among mono-substituted derivatives; however, the electron-withdrawing group 4-fluorobenzyl at C10 (**9d**) improved the affinity of the derivative for galectin-8N down to the dissociation constant of around 180 μM. Meanwhile, regardless of being mono-substituted or di-substituted, almost all the tricyclic compounds exhibited affinity for galectin-1. Benzyl group modification exerted positive effects on

Table 1 Galectin affinities of tricyclic carbohydrate−benzene hybrids (K_d, μM)

Cpd	Galectin-1	Galectin-3	Galectin-4C	Galectin-4N	Galectin-8N	Galectin-9C	Galectin-9N
5	890 ± 140	≫2000	840 ± 60	≫1000	2100 ± 320	≫1000	≫1000
6	1200 ± 120	≫2000	1600 ± 220	900 ± 87	250 ± 22	≫2000	≫2000
8a	2900 ± 580	≫8000	3700 ± 650	≫6000	≈10 000	≈5000	≫6000
8b	760 ± 35	≫2000	≫3000	≫3000	≫2000	≫2000	≫2000
8c	≫6000	2700 ± 440	≫6000	≈10 000	330 ± 18	2800 ± 290	≫6000
8d	1100 ± 320	≫2000	≈3000	870 ± 81	≫2000	≫2000	≫2000
8e	310 ± 57	≫2000	na[a]	na	1500 ± 260	na	na
9a	840 ± 85	≫2000	1100 ± 22	1500 ± 200	440 ± 47	≫2000	≫2000
9b	140 ± 14	≫2000	na	na	240 ± 49	na	na
9c	1500 ± 11	≫2000	1700 ± 430	≫1000	640 ± 58	≫1000	≫1000
9d	420 ± 61	4100 ± 370	≈3000	≫1000	180 ± 44	≫1000	≫1000
10[b]	>10 000	4400	10 000	6600	6300	8600	3300
1[b]	<0.01 (ref. 27)	∼0.0011 (ref. 27)	na	na	na	na	na
2[b]	48 ± 4.4 (ref. 21)	1.27 ± 0.07 (ref. 21)	43 ± 5.7 (ref. 21)	43 ± 7.1 (ref. 21)	1.5 ± 0.08 (ref. 21)	14 ± 1.3 (ref. 21)	2.06 ± 0.09 (ref. 21)

[a] Not available. [b] Reference compounds.

the binding activities, and **8e** and **9b** were the best galectin-1 inhibitors. Similar affinity trends were observed for galectin-1; however, for galectin-8N, *p*-fluorobenzyl **9d** was a more potent inhibitor than *p*-methoxybenzyl **9c**. Moreover, the two compounds **5** and **6** containing iodine atoms displayed obvious affinity for galectin-4C and galectin-4N, respectively, with a K_d value below 1000 μM.

2.3 Molecular docking of 9d with galectin-1 and galectin-8N

In order to analyze the possible binding modes of **9d** with galectin-1, galectin-3, and galectin-8N, molecular docking was performed.

In general, **9d** is located in the CRD of galectin-1 and galectin-8N, and its saccharide structure coincides with the galactose part of D-lactose (Fig. 2a and c), respectively. Polar


Fig. 2 Molecular docking of **9d** with galectins. (a) **9d** is shown with green carbons, and lactose is shown with magenta carbons in the galectin-1 CRD. (b) Interactions between **9d** and CRD of galectin-1. (c) **9d** is shown with green carbons and lactose is shown with magenta carbons in the galectin-8N CRD. (d) Interactions between **9d** and CRD of galectin-8N.


Fig. 3 Comparison between the complexes of **9d** with galectin-1 (a), galectin-3 (b), and galectin-8N (c).

interactions are mainly the hydrogen bonds between the galactopyranose hydroxyl groups at C4 and C6 and the nearby residues (Fig. 2b and d). The C4 hydroxyl group of **9d** forms hydrogen bonds with the galectin-1 residues Arg-48 and His-44, whereas the C6 hydroxyl group interacts with the residues Asn-61 and Glu-71. In the case of galectin-8N, the C4 hydroxyl group of **9d** forms hydrogen bonds with the galectin-8N residues Arg-45, Arg-69, and His-65, whereas the C6 hydroxyl group interacts with the residues Asn-79 and Glu-89.

From the docking poses of **9d** in its complex with galectin-1, 3, and 8N (Fig. 3), it can be observed that the benzene parts of the tricyclic skeleton were close to the electropositive arginine-containing regions, which could contribute to the cation–π interactions. The relatively flat surface consisted of Glu-71 and Arg-48, which seemed to favor the stacking of 4-fluorobenzyl in galectin-1 *via* π–π or cation–π interactions (Fig. 3a). Moreover, a similar trend could be observed in galectin-8N, and the surface was composed of Glu-89 and Arg-69 (Fig. 3c). On the contrary, steric hindrance occurred outside the CRD groove in galectin-3, which might not be conducive to the π-interactions (Fig. 3b).

3 Experimental

3.1 Synthesis

3.1.1 General methods. All solvents were well-dried before use according to standard methods, and commercial reagents

were directly used without further purification. TLC was performed on silica-gel 60 F254 aluminum sheets (Merck) with detection by UV and/or 10% sulfuric acid in ethanol. The purification of compounds was carried out by silica-gel column chromatography. A microwave reaction was performed in the Biotage Initiator$^+$. ^{1}H NMR, ^{13}C NMR, 2D COSY, HMQC, and HMBC spectra were obtained via the Bruker DRX 400 MHz or Bruker DRX 500 MHz spectrometer at ambient temperature using CDCl$_3$, DMSO-d_6 or CD$_3$OD as a solvent. HRMS was recorded using the Waters Micromass Q-TOF mass spectrometer.

All the final compounds were of >95% purity according to the HPLC analysis (Agilent Series 1100 system, Zorbax Eclipse XDB-C18 column, and H$_2$O–MeCN gradient 5–95% with 0.1% TFA).

3.1.2 Synthesis of the protected di-substituted tricyclic compounds 7a–7c.
The compound **3** (ref. 29) (115 mg, 0.33 mmol) and substituted alkyne (3.3 mmol) were dissolved in a mixture of DMF/MeCN/NMP (10 mL/10 mL/1.4 mL) solution, and then, the catalytic reagent Pd(PPh$_3$)$_4$ (41 mg, 35 μmol), [(t-Bu)$_3$PH]BF$_4$ (10 mg, 35 μmol), and diisopropylamine (184 μL, 1.32 mmol) were added. The reaction mixture was stirred in a microwave-reactor (absorption level was set as very high) for 3 h at 120 °C. The reaction was stopped by the addition of brine, and the aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organic layer was washed with water and brine and then dried over anhydrous Na$_2$SO$_4$. After the solvent was removed by rotary evaporation, the residue was purified by column chromatography (heptane : ethyl acetate = 3 : 1) to afford the compounds 7a–7c.

7a. White solid; yield: 44%; ^{1}H NMR (400 MHz, CDCl$_3$): δ = 7.25–7.16 (m, 5H, Ph), 6.68 (s, 1H, 10-H), 5.62 (s, 1H, 7-H), 5.22–5.16 (m, 2H, 8-H$_a$, 3-H), 4.94 (dd, J = 11.6 Hz, 1.6 Hz, 1H, 8-H$_b$), 4.60–4.56 (m, 2H, 6-H$_a$, 4-H), 4.20 (dd, J = 12.0 Hz, 1.2 Hz, 1H, 6-H$_b$), 4.12 (d, J = 1.4 Hz, 1H, 5-H), 2.76–2.61 (m, 4H, CH$_2$), 1.23 (t, J = 7.6 Hz, 3H, CH$_3$), 1.18 (t, J = 7.6 Hz, 3H, CH$_3$); ^{13}C NMR (100 MHz, CDCl$_3$): 149.3, 144.2, 137.7, 137.6, 119.2, 113.4, 101.2 (C-Ph, C-1, C-2, C-7, C-9, C-10, C-11, C-12), 129.0, 128.0, 126.6 (C-Ph), 77.3 (C-3), 74.4 (C-8), 72.4 (C-4), 70.2 (C-6), 69.0 (C-5), 26.2 (CH$_2$), 18.5 (CH$_2$), 16.2 (CH$_3$), 14.6 (CH$_3$). HRMS: calculated for C$_{22}$H$_{24}$O$_4$ ([M + Na]$^+$): 375.1567; found 375.1570.

7b. White solid; yield: 38%; ^{1}H NMR (400 MHz, CDCl$_3$): δ = 7.25–7.15 (m, 5H, Ph), 6.66 (s, 1H, 10-H), 5.61 (s, 1H, 7-H), 5.22–5.15 (m, 2H, 8-H$_a$, 3-H), 4.94 (dd, J = 11.6 Hz, 1.8 Hz, 1H, 8-H$_b$), 4.59 (dd, J = 3.6 Hz, 1.4 Hz, 1H, 4-H), 4.57 (dd, J = 12.3 Hz, 1.8 Hz, 1H, 6-H$_a$), 4.20 (dd, J = 12.3 Hz, 1.3 Hz, 1H, 6-H$_b$), 4.10 (d, J = 1.3 Hz, 1H, 5-H), 2.72–2.52 (m, 4H, CH$_2$), 1.66–1.58 (m, 4H, CH$_2$), 0.99 (t, J = 7.4 Hz, 3H, CH$_3$), 0.97 (t, J = 7.4 Hz, 3H, CH$_3$); ^{13}C NMR (100 MHz, CDCl$_3$): 149.6, 143.2, 137.8, 137.5, 125.0, 119.2, 114.2, 101.3 (C-Ph, C-1, C-2, C-7, C-9, C-10, C-11, C-12), 129.2, 128.2, 126.8 (C-Ph), 77.5 (C-3), 74.5 (C-8), 72.4 (C-4), 70.3 (C-6), 69.1 (C-5), 35.6 (CH$_2$), 27.5 (CH$_2$), 25.1 (CH$_2$), 23.4 (CH$_2$), 14.6 (CH$_3$), 14.3 (CH$_3$). HRMS: calculated for C$_{24}$H$_{28}$O$_4$ ([M + Na]$^+$): 403.1880; found: 403.1890.

7c. Colorless oil; yield: 43%; ^{1}H NMR (400 MHz, CDCl$_3$): δ = 7.28–7.22 (m, 5H, Ph), 7.17 (s, 1H, 10-H), 5.64 (s, 1H, 7-H), 5.23–5.18 (m, 2H, 8-H$_a$, 3-H), 4.94 (dd, J = 13.0 Hz, 3.0 Hz, 1H, 8-H$_b$), 4.62 (dd, 1H, J = 3.6 Hz, 1.3 Hz, 4-H), 4.58 (dd, J = 12.4 Hz, 1.8 Hz, 1H, 6-H$_b$), 4.20 (dd, J = 12.4 Hz, 1.4 Hz, 1H, 6-H$_b$), 4.13

(d, J = 1.4 Hz, 1H, 5-H), 0.46 (s, 9H, CH$_3$), 0.39 (s, 9H, CH$_3$); ^{13}C NMR (100 MHz, CDCl$_3$): 157.3, 149.2, 141.0, 137.7, 121.5 (C-2, C-7, C-9, C-11, C-12), 129.2, 128.8, 128.1, 126.9 (C-Ph), 120.7 (C-10), 101.5 (C-1), 77.6 (C-3), 74.5 (C-8), 72.2 (C-4), 69.9 (C-6), 69.2 (C-5), 3.1 (CH$_3$), 3.0 (CH$_3$). HRMS: calculated for C$_{24}$H$_{32}$O$_4$Si$_2$ ([M + Na]$^+$): 463.1731; found: 463.1740.

3.1.3 Synthesis of the di-substituted compounds 8a–8c.
The compounds **7a–7c** (0.1 mol) were dissolved in methanol (10 mL), and then, 0.2 M HCl was added. The mixture was stirred at 55 °C for 6 h. After being cooled to room temperature, the reaction mixture was neutralized by the addition of a saturated NaHCO$_3$ solution. The resulting mixture was extracted with ethyl acetate (3 × 15 mL), and then, the combined organic layers were washed with water and brine. After being dried over Na$_2$SO$_4$, the solvent was removed by rotary evaporation. The residue was purified by column chromatography (heptane : ethyl acetate = 3 : 5) to afford **8a–8c**.

8a. White solid; yield: 32%; ^{1}H NMR (400 MHz, DMSO-d_6): δ = 6.63 (s, 1H, 9-H), 5.01–4.96 (m, 2H, 7-H$_a$, 3-H), 4.87 (t, J = 5.6 Hz, 1H, OH), 4.79–4.76 (m, 2H, 7-H$_b$, OH), 4.19 (t, J = 1.4 Hz, 1H, 4-H), 4.05 (t, J = 6.4 Hz, 1H, 5-H), 3.76–3.70 (m, 2H, 6-H$_a$, 6-H$_b$), 2.69–2.67 (m, 2H, CH$_2$), 2.34–2.33 (m, 2H, CH$_2$), 1.14 (t, J = 7.5 Hz, 3H, CH$_3$), 1.04 (t, J = 7.5 Hz, 3H, CH$_3$); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 149.2, 143.4, 138.7, 124.9, 118.8 (C-1, C-2, C-8, C-10, C-11), 114.3 (C-9), 77.8, 76.9 (C-3, C-5), 74.2 (C-7), 65.2 (C-4), 63.5 (C-6), 24.9, 18.1 (CH$_2$), 16.8, 14.5 (CH$_3$); HRMS: calculated for C$_{15}$H$_{20}$O$_4$ ([M + Na]$^+$): 287.1254; found: 287.1254.

8b. White solid; yield: 40%; ^{1}H NMR (400 MHz, CD$_3$OD): δ = 6.65 (s, 1H, 9-H), 5.10–5.07 (m, 2H, 3-H, 7-H$_a$), 4.87–4.84 (m, 1H, 7-H$_b$), 4.33 (dd, J = 3.4 Hz, 0.8 Hz, 1H, 4-H), 4.11 (t, J = 6.4 Hz, 1H, 5-H), 3.92 (d, J = 6.3 Hz, 2H, 6-H), 2.63–2.54 (m, 4H, CH$_2$), 1.59–1.50 (m, 4H, CH$_2$), 0.97 (t, J = 7.4 Hz, 3H, CH$_3$), 0.96 (t, J = 7.4 Hz, 3H, CH$_3$); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 150.7, 143.8, 140.0, 125.5, 121.2 (C-1, C-2, C-8, C-10, C-11), 115.0 (C-9), 79.8, 79.4 (C-3, C-5), 74.8 (C-7), 64.8 (C-4), 62.6 (C-6), 36.4, 28.2, 26.2, 24.5 (CH$_2$), 14.6, 14.5 (CH$_3$); HRMS: calculated for C$_{17}$H$_{24}$O$_4$ ([M + Na]$^+$): 315.1567; found: 315.1579.

8c. White solid; yield: 43%; ^{1}H NMR (400 MHz, CDCl$_3$): δ = 6.99 (s, 1H, 11-H), 6.90 (s, 1H, 9-H), 5.22–5.18 (m, 1H, 7-H$_a$), 5.12–5.11 (m, 1H, 3-H), 4.96 (dd, J = 11.9 Hz, 1.8 Hz, 1H, 7-H$_b$), 4.41 (dd, J = 3.6 Hz, 0.8 Hz, 1H, 4-H), 4.19–4.12 (m, 2H, 5-H, 6-H$_a$), 4.06 (dd, J = 11.2 Hz, 4.2 Hz, 1H, 6-H$_b$), 0.25 (s, 9H, CH$_3$); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 151.1, 144.4, 141.8, 122.7 (C-1, C-2, C-8, C-10), 118.2, 117.0 (C-9, C-11), 77.8, 77.2, 65.3 (C-3, C-4, C-5), 74.4 (C-7), 63.5 (C-6), −0.9 (CH$_3$); HRMS: calculated for C$_{14}$H$_{20}$O$_4$Si ([M + Na]$^+$): 303.1023; found: 303.1024.

3.1.4 Synthesis of the benzylidene-protected di-iodo tricyclic compound 4.
A solution of **7c** (123 mg, 0.28 mmol) in DCM (5 mL) was stirred in an ice bath, and iodine monochloride (29 μL, 0.56 mmol) in 2 mL DCM was added to the abovementioned solution over 10 min. The mixture was allowed to stir at room temperature (r.t.) for 1–2 h and then quenched by a saturated KHSO$_4$ solution. The organic layer was separated and then dried over anhydrous Na$_2$SO$_4$. After the solvent was removed by rotary evaporation, the crude compound **4** was afforded by column chromatography (heptane : ethyl acetate = 3 : 1) as a white solid (72 mg, 39%). ^{1}H NMR (400 MHz, CDCl$_3$): δ = 7.44 (s, 1H, 10-H),

7.28–7.27 (m, 3H, Ph-H), 7.23–7.21 (m, 2H, Ph-H), 5.63 (s, 1H, 7-H), 5.16–5.14 (m, 2H, 3-H, 8-H$_a$), 4.94 (dd, J = 12.2 Hz, 2.2 Hz, 1H, 8-H$_b$), 4.66 (dd, J = 12.4 Hz, 1.6 Hz, 1H, 6-H$_a$), 4.62 (dd, 1H, J = 3.6 Hz, 1.2 Hz, 4-H), 4.26–4.22 (m, 2H, 5-H, 6-H$_b$); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 151.9, 142.7, 137.2, 129.2, 128.1, 126.5, 124.8, 121.7, 108.8 (C-2, C-7, C-9, C-11, C-12, C-10, C-Ph), 101.2 (C-1), 77.0 (C-3), 73.6 (C-8), 71.9 (C-4), 71.4 (C-5), 69.8 (C-6); HRMS: calculated for C C$_{18}$H$_{14}$I$_2$O$_4$ ([M + Na]$^+$): 570.8874; found: 570.8871.

3.1.5 Synthesis of the di-iodo tricyclic compound 5. The compound **4** (72 mg, 0.13 mmol) was dissolved in 4 mL methanol, and 0.2 M HCl solution was added to it to adjust the pH < 3. The reaction was maintained at 55 °C for 10 h. After cooling to r.t., the saturated NaHCO$_3$ solution was added. The mixture was extracted by EtOAc (15 mL × 3). Then, the combined organic phase was washed with brine (25 mL × 2) followed by drying over anhydrous Na$_2$SO$_4$. After the solvent was removed by rotary evaporation, the residue was purified by column chromatography (heptane : ethyl acetate = 1 : 2) to obtain the white solid **5** (34 mg, 57%). ^{1}H NMR (400 MHz, DMSO-d_6): δ = 7.46 (s, 1H, 9-H), 5.11 (br, 1H, OH), 5.04 (d, J = 2.7 Hz, 1H, 3-H), 4.99–4.95 (m, 2H, OH, 7-H$_a$), 4.80 (dd, J = 12.7 Hz, 1.8 Hz, 1H, 7-H$_b$), 4.22–4.19 (m, 2H, 6-H$_a$, 4-H), 3.77–3.68 (m, 2H, 5-H, 6-H$_b$); ^{13}C NMR (100 MHz, DMSO-d_6): δ = 152.0, 144.1, 124.0, 123.9, 108.7 (C-1, C-2, C-8, C-10, C-11), 92.8, 80.6, 78.1 (C-9, C-3, C-5), 72.4 (C-7), 61.8 (C-4), 59.7 (C-6); HRMS: calculated for C$_{11}$H$_{10}$I$_2$O$_4$ ([M + Na]$^+$): 482.8561; found: 482.8562.

3.1.6 Synthesis of the di-substituted compounds 8d–8e. To a mixture of compound **5** (46 mg, 0.10 mmol), substituted benzyl(tributyl)stannane (0.35 mmol), and triethylamine (50 μL) in 10 mL DMF, catalytic amount of CuI and Pd(PPh$_3$)$_4$ were added. After being stirred under a nitrogen atmosphere at 75 °C for 20 h, the mixture was cooled to r.t. and concentrated to dryness. The crude product was purified by column chromatography (heptane : ethyl acetate = 3 : 1) to afford the compounds **8d–8e**.

8d. White solid; yield: 43%; ^{1}H NMR (400 MHz, CD$_3$OD): δ = 6.84 (s, 1H, 9-H), 5.09–5.05 (m, 2H, 7-H$_a$, 3-H), 4.86–4.83 (m, 1H, 7-H$_b$), 4.35 (dd, J = 3.3 Hz, 0.8 Hz, 1H, 4-H), 4.18 (t, J = 6.4 Hz, 1H, 5-H), 3.99–3.91 (m, 2H, 6-H$_a$, 6-H$_b$), 2.09 (s, 3H, CH$_3$), 2.05 (s, 3H, CH$_3$); ^{13}C NMR (100 MHz, CD$_3$OD): δ = 153.2, 142.1, 129.8, 123.8, 112.2 (C-1, C-2, C-8, C-10, C-11), 118.0 (C-9), 94.1, 89.4, 80.5, 74.6 (C≡C), 79.9, 79.7 (C-3, C-5), 74.8 (C-7), 64.4 (C-4), 62.2 (C-6), 4.4, 4.0 (CH$_3$); HRMS: calculated for C$_{17}$H$_{16}$O$_4$ ([M + Na]$^+$): 307.0941; found: 307.0948.

8e. White solid; yield: 42%; ^{1}H NMR (400 MHz, CDCl$_3$): δ = 7.31–7.05 (m, 10H, Ph), 6.63 (s, 1H, 9-H), 5.19–5.16 (m, 2H, 7-H$_a$, 3-H), 4.94–4.92 (m, 1H, 7-H$_b$), 4.43–4.42 (m, 1H, 4-H), 4.18 (t, J = 4.8 Hz, 1H, 5-H), 4.06–3.88 (m, 6H, CH$_2$, 6-H$_a$, 6-H$_b$); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 149.9, 142.2, 140.8, 140.6, 140.0, 128.9, 128.6, 128.5, 128.3, 126.2, 126.0, 123.4, 120.3 (C-1, C-2, C-8, C-10, C-11, C-Ph), 115.8 (C-9), 78.2 (C-3), 77.5 (C-5), 74.4 (C-7), 65.6 (C-4), 63.7 (C-6), 39.4, 31.1 (CH$_2$); HRMS: calculated for C$_{25}$H$_{24}$O$_4$ ([M + Na]$^+$): 411.1567; found: 411.1566.

3.1.7 Synthesis of the mono-iodo tricyclic compounds 6. To a stirred solution of **8c** (42 mg, 0.15 mmol) in 5 mL DCM in an ice bath, ICl (49 mg, 0.30 mmol) in 6 mL DCM was added over 10 min. The mixture was allowed to stir at r.t. for 1 h and then

poured into saturated KHSO$_4$. The resulting mixture was extracted with DCM (20 mL × 3) and dried over anhydrous Na$_2$SO$_4$. After the solvent was removed by rotary evaporation, the residue was purified by column chromatography (heptane : ethyl acetate = 3 : 1) to obtain the white solid **6** (33 mg, 66%). ^{1}H NMR (400 MHz, MeOD): δ = 7.19 (s, 1H, 11-H), 7.02 (s, 1H, 9-H), 5.12–5.05 (m, 2H, 3-H, 7-H$_a$), 4.90 (m, 1H, 7-H$_b$), 4.33 (dd, J = 3.6, 0.8 Hz, 1H, 4-H), 4.16 (t, J = 6 Hz, 1H, 5-H), 3.95–3.87 (m, 2H, 6-H$_a$, 6-H$_b$); ^{13}C NMR (100 MHz, MeOD): δ = 153.6, 145.5, 124.6 (C-1, C-2, C-8), 123.7, 122.0 (C-9, C-11), 94.2 (C-10), 80.3 (C-5), 79.6 (C-3), 74.3 (C-7), 64.7 (C-4), 62.6 (C-6); HRMS: calculated for C$_{11}$H$_{11}$IO$_4$ ([M + Na]$^+$): 356.9594; found: 356.9606.

3.1.8 Synthesis of the mono-substituted compounds 9a–9d. The compound **6** (33 mg, 0.10 mmol), substituted benzyl(tributyl)stannane (0.20 mmol), and triethylamine (35 μL) were dissolved in 10 mL DMF, and then, catalytic amount of CuI and Pd(PPh$_3$)$_4$ were added. After being stirred under a nitrogen atmosphere at 95 °C for 14 h, the mixture was cooled and concentrated to dryness. The crude product was purified by column chromatography (heptane : ethyl acetate = 3 : 1) to afford the compounds **9a–9d**.

9a. White solid; yield: 32%; ^{1}H NMR (400 MHz, CDCl$_3$): δ = 6.87 (s, 1H, 11-H), 6.77 (s, 1H, 9-H), 5.22–5.05 (m, 2H, 3-H, 7-H$_a$), 4.92 (d, J = 11.9 Hz, 1H, 7-H$_b$), 4.40 (d, J = 3.2 Hz, 1H, 4-H), 4.24–4.13 (m, 3H, 5-H, 6-H$_a$, 6-H$_b$), 2.04 (d, J = 5.6 Hz, 3H, CH$_3$); ^{13}C NMR (100 MHz, CDCl$_3$): δ = 151.1, 141.9, 126.4, 121.7 (C-1, C-2, C-8, C-10), 117.3, 115.8 (C-9, C-11), 85.7, 79.8 (C≡C), 77.8 (C-3), 77.5 (C-5), 74.2 (C-7), 65.3 (C-4), 63.5 (C-6), 4.5 (CH$_3$); HRMS: calculated for C$_{14}$H$_{14}$O$_4$ ([M + Na]$^+$): 269.0784; found: 269.0789.

9b. White solid; yield: 29%; ^{1}H NMR (400 MHz, CDCl$_3$): δ = 7.31–7.27 (m, 2H, Ph), 7.22–7.18 (m, 3H, Ph), 6.68 (s, 1H, 11-H), 6.59 (s, 1H, 9-H), 5.17–5.10 (m, 2H, 3-H, 7-H$_a$), 4.85 (dd, J = 11.6 Hz, 1.6 Hz, 1H, 7-H$_b$), 4.40–4.39 (m, 1H, 4-H), 4.17–4.11 (m, 2H, 5-H, 6-H$_a$), 4.08–4.04 (m, 1H, 6-H$_b$), 3.96–3.85 (s, 2H, CH$_2$); ^{13}C NMR (101 MHz, MeOD): δ = 151.4, 144.8, 142.3, 129.1, 126.4, 120.5 (C-1, C-2, C-8, C-10, C-Ph), 114.5 (C-11), 113.0 (C-9), 77.7, 77.4 (C-3, C-5), 74.4 (C-7), 65.4 (C-4), 63.6 (C-6), 42.4 (CH$_2$); HRMS: calculated for C$_{18}$H$_{18}$O$_4$ ([M + Na]$^+$): 321.1097; found: 321.1101.

9c. White solid; yield: 33%; ^{1}H NMR (400 MHz, CD$_3$OD): δ = 7.11–7.08 (m, 2H, Ph), 6.83–6.79 (m, 2H, Ph), 6.66 (s, 1H, 11-H), 6.47 (s, 1H, 9-H), 5.10–5.07 (m, 2H, 3-H, 7-H$_a$), 4.85 (m, 1H, 7-H$_b$), 4.30 (dd, J = 3.3 Hz, 0.8 Hz, 1H, 4-H), 4.12 (t, J = 6.2 Hz, 1H, 5-H), 3.94–3.85 (m, 4H, CH$_2$, 6-H$_a$, 6-H$_b$), 3.75 (s, 1H, OCH$_3$); ^{13}C NMR (101 MHz, MeOD): δ = 152.8, 146.1, 143.5, 134.8 (C-1, C-2, C-8, C-Ph), 130.8 (C-Ph), 122.0 (C-10), 114.8 (C-Ph, C-11), 113.4 (C-9), 79.8, 79.6 (C-3, C-5), 74.9 (C-7), 65.0 (C-4), 62.7 (C-6), 55.7 (OCH$_3$), 42.2 (CH$_2$); HRMS: calculated for C$_{19}$H$_{20}$O$_5$ ([M + Na]$^+$): 351.1202; found: 351.1202.

9d. White solid; yield: 40%; ^{1}H NMR (500 MHz, MeOD): δ = 7.21–7.18 (m, 2H, Ph), 6.97 (t, J = 8.5 Hz, 2H, Ph), 6.67 (s, 1H, 11-H), 6.48 (s, 1H, 9-H), 5.10–5.08 (m, 2H, 3-H, 7-H$_a$), 4.31 (d, J = 3.3 Hz, 1H, 4-H), 4.13 (t, J = 6.2 Hz, 1H, 5-H), 3.93–3.86 (m, 4H, CH$_2$, 6-H$_a$, 6-H$_b$); ^{13}C NMR (126 MHz, MeOD): δ = 162.8 (C-Ph, J = 244 Hz), 152.9, 145.3, 143.7, 138.8 (C-1, C-2, C-8, C-Ph), 131.5 (C-Ph, J = 7.7 Hz), 122.2 (C-10), 115.9 (C-Ph, J = 21 Hz), 114.9 (C-11), 113.4 (C-9), 79.8, 79.6 (C-3, C-5), 74.9 (C-7), 65.0 (C-4), 62.7

(C-6), 42.1 (CH$_2$); HRMS: calculated for C$_{18}$H$_{17}$FO$_4$ ([M + Na]$^+$): 339.1003; found: 339.1009.

3.2 Galectin binding evaluations

3.2.1 Competitive fluorescence polarization experiments. Human galectin-1, galectin-3, galectin-4N, galectin-4C, galectin-8N, galectin-9N, and galectin-9C were expressed and purified as previously described.[30] Fluorescence polarization experiments were performed using the PHERAstar FS plate reader (software version 2.10 R3), and the fluorescence anisotropy of fluorescein-tagged probes was measured by excitation at 485 nm and emission at 520 nm. The K_d values were determined using GraphPad Prism under specific conditions for each galectin as described below. The synthesized compounds were dissolved in neat DMSO at 100 mM and diluted in PBS to 3–6 different concentrations, and each concentration was tested in duplicate. Methyl β-D-galactoside was used as a reference. Experiments were performed 3–10 times, and the average values of K_d and SEM were calculated from 10 to 30 single-point measurements, showing 10–90% inhibition.

Galectin-1 affinities. Experiments were conducted at 20 °C using galectin-1 at 0.50 μM and the fluorescent probe 3,3′-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3′-(3,5-dimethoxy-benzamido)-1,1′-sulfanediyl-di-β-D-galactopyranoside at 0.10 μM.

Galectin-3 affinities. Experiments were performed at 20 °C using galectin-3 at 0.20 μM and the fluorescent probe 3,3′-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3′-(3,5-dimethoxybenzamido)-1,1′-sulfanediyl-di-β-D-galactopyranoside at 0.02 μM or with galectin-3 at 1.0 μM and 2-(fluorescein-5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy-α-D-galactopyranosyl-(1–3)-[α-L-fucopyranosyl-(1–2)]-β-D-galactopyranosyl-(1–4)-β-D-glucopyranoside at 0.10 μM.

Galectin-4C affinities. Experiments were conducted at 20 °C using galectin-4C at 0.50 μM and the fluorescent probe 2-(fluorescein-5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy-α-D-galactopyranosyl-(1–3)-[α-L-fucopyranosyl-(1–2)]-β-D-galactopyranosyl-(1–4)-β-D-glucopyranoside at 0.1 μM.

Galectin-4N affinities. Experiments were carried out at 20 °C using galectin-4N at 3.0 μM and the fluorescent probe 3,3′-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3′-(3,5-dimethoxy-benzamido)-1,1′-sulfanediyl-di-β-D-galactopyranoside at 0.10 μM.

Galectin-8N affinities. Experiments were performed at 20 °C using galectin-8N at 0.40 μM and the fluorescent probe 2-(fluorescein-5-yl-carbonylamino) ethyl β-D-galactopyranosyl-(1–4)-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1–3)-β-D-galactopyranosyl-(1–4)-β-D-glucopyranoside at 0.1 μM.

Galectin-9C affinities. Experiments were conducted at 20 °C using galectin-9C at 2.0 μM and the fluorescent probe 3,3′-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3′-(3,5-dimethoxy-benzamido)-1,1′-sulfanediyl-di-β-D-galactopyranoside at 0.10 μM.

Galectin-9N affinities. Experiments were performed at 20 °C using galectin-9N at 1.0 μM and the fluorescent probe 2-(fluorescein-5-yl-carbonylamino)-ethyl β-D-galactopyranosyl-(1–4)-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1–3)-β-D-galactopyranosyl-(1–4)-β-D-glucopyranoside at 0.1 μM.

3.3 Molecular docking

The X-ray crystal structures of human galectin-1, galectin-3, and N-terminal domain of galectin-8 with D-lactose (PDB ID 1gzw,[32] 3aye[33] and 2yxs) were used to investigate the binding modes of these galectin proteins with the compound **9d**. In brief, the proteins were prepared using Autodock Tools 1.5.6 by deleting water molecules, adding polar hydrogens, and assigning Gasteiger charges. The original ligand D-lactose was used to define the binding site, and the box was set using D-lactose as a grid center (galectin-1: center_x = 55.497, center_y = 26.987, center_z = 23.331; size_x = 15, size_y = 15, size_z = 15; galectin-3: center_x = −13.334, center_y = 7.803, center_z = −26.075; size_x = 15, size_y = 15, size_z = 15; galectin-8N: center_x = 14.183, center_y = 24.913, center_z = −7.492; size_x = 15, size_y = 15, size_z = 15). Autodock vina 1.1.2 (ref. 34) was used to perform the docking, and the exhaustiveness value was set to 20.

4 Conclusions

Herein, a series of tricyclic carbohydrate–benzene hybrids were synthesized from D-galactose, and derivatizations at C10 and C11 were implemented *via* iodo-intermediates. Furthermore, their galectin binding activities were evaluated by the competitive fluorescence polarization assay, and the results indicated that most of the hybrid derivatives exhibited selective affinity for galectin-1 and galectin-8N over galectin-3, 4C, 4N, 9C, and 9N. Structure–activity analysis revealed that the C10-mono-substituted compounds displayed better affinity for galectin-8N when compared with the C10, C1-di-substituted, and compounds with (substituted) benzyl groups were good for activity enhancement when compared with other aliphatic alkyl groups. The relatively flat surface near the groove of galectin-1 or galectin-8N CRD was beneficial to the binding since the residues might interact with the benzyl group *via* cation–π or π–π stackings. Hence, the C10-benzyl tricyclic carbohydrate–benzene hybrids are promising scaffolds for the discovery of selective galectin-1 and galectin-8N inhibitors.

Conflicts of interest

UJN is a shareholder in Galecto Biotech AB, Sweden.

Acknowledgements

Notes and references

1 H. Leffler, S. Carlsson, M. Hedlund, Y. Qian and F. Poirier, *Glycoconjugate J.*, 2002, **19**, 433–440.

2 S. H. Barondes, V. Castronovo, D. Cooper, R. D. Cummings, K. Drickamer, T. Feizi, M. A. Gitt, J. Hirabayashi, C. Hughes, K.-i. Kasai, H. Leffler, F.-T. Liu, R. Lotan, A. M. Mercurio, M. Monsigny, S. Pillai, F. Poirer, A. Raz, P. W. J. Rigby, J. M. Rini and J. L. Wang, *Cell*, 1994, **76**, 597–598.

3 R. C. Hughes, *Biochimie*, 2001, **83**, 667–676.

4 L. Wang and X. Guo, *Biomed. Pharmacother.*, 2016, **78**, 165–171.

5 T. Lei, S. Moos, J. Klug, F. Aslani, S. Bhushan, E. Wahle, S. Fröhlich, A. Meinhardt and M. Fijak, *Sci. Rep.*, 2018, **8**, 3741–3755.

6 D. Daley, V. R. Mani, N. Mohan, N. Akkad, A. Ochi, D. W. Heindel, K. B. Lee, C. P. Zambirinis, G. S. D. B. Pandian, S. Savadkar, A. Torres-Hernandez, S. Nayak, D. Wang, M. Hundeyin, B. Diskin, B. Aykut, G. Werba, R. M. Barilla, R. Rodriguez, S. Chang, L. Gardner, L. K. Mahal, B. Ueberheide and G. Miller, *Nat. Med.*, 2017, **23**, 556–567.

7 S. Nakahara, N. Oka and A. Raz, *Apoptosis*, 2005, **10**, 267–275.

8 N. L. Perillo, K. E. Pace, J. J. Seilhamer and L. G. Baum, *Nature*, 1995, **378**, 736–739.

9 J. Wang, J. Xia, F. Zhang, Y. Shi, Y. Wu, H. Pu, A. K. F. Liou, R. K. Leak, X. Yu, L. Chen and J. Chen, *Sci. Rep.*, 2015, **5**, 9621–9630.

10 M. Ouellet, S. Mercier, I. Pelletier, S. Bounou, J. Roy, J. Hirabayashi, S. Sato and M. J. Tremblay, *J. Immunol.*, 2005, **174**, 4120–4126.

11 J. M. Cousin and M. J. Cloninger, *Int. J. Mol. Sci.*, 2016, **17**, 1566–1587.

12 K. Ito, K. Stannard, E. Gabutero, A. M. Clark, S.-Y. Neo, S. Onturk, H. Blanchard and S. J. Ralph, *Cancer Metastasis Rev.*, 2012, **31**, 763–778.

13 T. L. M. Thurston, M. P. Wandel, N. von Muhlinen, Á. Foeglein and F. Randow, *Nature*, 2012, **482**, 414–418.

14 W.-S. Chen, Z. Cao, S. Sugaya, M. J. Lopez, V. G. Sendra, N. Laver, H. Leffler, U. J. Nilsson, J. Fu, J. Song, L. Xia, P. Hamrah and N. Panjwani, *Nat. Commun.*, 2016, **7**, 11302–11320.

15 G. Choufani, N. Nagy, S. Saussez, H. Marchant, P. Bisschop, M. Burchert, A. Danguy, S. Louryan, I. Salmon, H. J. Gabius, R. Kiss and S. Hassid, *Cancer*, 1999, **86**, 2353–2363.

16 D. Obino, L. Fetler, A. Soza, O. Malbec, J. J. Saez, M. Labarca, C. Oyanadel, F. Del Valle Batalla, N. Goles, A. Chikina, D. Lankar, F. Segovia-Miranda, C. Garcia, T. Léger, A. Gonzalez, M. Espéli, A.-M. Lennon-Duménil and M.-I. Yuseff, *Cell Rep.*, 2018, **25**, 3110–3122.

17 F. Ferragut, A. J. Cagnoni, L. L. Colombo, C. Sánchez Terrero, C. Wolfenstein-Todel, M. F. Troncoso, S. I. Vanzulli, G. A. Rabinovich, K. V. Mariño and M. T. Elola, *Biochim. Biophys. Acta*, 2019, **1866**, 1338–1352.

18 E. Pardo, F. Barake, J. A. Godoy, C. Oyanadel, S. Espinoza, C. Metz, C. Retamal, L. Massardo, C. Tapia-Rojas, N. C. Inestrosa, A. Soza and A. González, *Mol. Neurobiol.*, 2019, **56**, 7774–7788.

19 V. Balan, P. Nangia-Makker and A. Raz, *Cancers*, 2010, **2**, 592–610.

20 H. Blanchard, X. Yu, P. M. Collins and K. Bum-Erdene, *Expert Opin. Ther. Pat.*, 2014, **24**, 1053–1065.

21 K. B. Pal, M. Mahanti, X. Huang, S. Persson, A. P. Sundin, F. R. Zetterberg, S. Oredsson, H. Leffler and U. J. Nilsson, *Org. Biomol. Chem.*, 2018, **16**, 6295–6305.

22 J. Tejler, F. Skogman, H. Leffler and U. J. Nilsson, *Carbohydr. Res.*, 2007, **342**, 1869–1875.

23 P. M. Collins, C. T. Öberg, H. Leffler, U. J. Nilsson and H. Blanchard, *Chem. Biol. Drug Des.*, 2012, **79**, 339–346.

24 J. Dion, F. Deshayes, N. Storozhylova, T. Advedissian, A. Lambert, M. Viguier, C. Tellier, C. Dussouy, F. Poirier and C. Grandjean, *ChemBioChem*, 2017, **18**, 782–789.

25 I. Cumpstey, A. Sundin, H. Leffler and U. J. Nilsson, *Angew. Chem., Int. Ed.*, 2005, **44**, 5110–5112.

26 T. Delaine, P. Collins, A. MacKinnon, G. Sharma, J. Stegmayr, V. K. Rajput, S. Mandal, I. Cumpstey, A. Larumbe, B. A. Salameh, B. Kahl-Knutsson, H. van Hattum, M. van Scherpenzeel, R. J. Pieters, T. Sethi, H. Schambye, S. Oredsson, H. Leffler, H. Blanchard and U. J. Nilsson, *ChemBioChem*, 2016, **17**, 1759–1770.

27 K. Peterson, R. Kumar, O. Stenstroem, P. Verma, P. R. Verma, M. Haakansson, B. Kahl-Knutsson, F. Zetterberg, H. Leffler, M. Akke, D. T. Logan and U. J. Nilsson, *J. Med. Chem.*, 2018, **61**, 1164–1175.

28 V. K. Rajput, A. MacKinnon, S. Mandal, P. Collins, H. Blanchard, H. Leffler, T. Sethi, H. Schambye, B. Mukhopadhyay and U. J. Nilsson, *J. Med. Chem.*, 2016, **59**, 8141–8147.

29 M. Leibeling, B. Milde, D. Kratzert, D. Stalke and D. B. Werz, *Chem.–Eur. J.*, 2011, **17**, 9888–9892.

30 P. Sörme, B. Kahl-Knutsson, M. Huflejt, U. J. Nilsson and H. Leffler, *Anal. Biochem.*, 2004, **334**, 36–47.

31 P. Sörme, B. Kahl-Knutson, U. Wellmar, U. J. Nilsson and H. Leffler, *Methods Enzymol.*, 2003, **362**, 504–512.

32 M. F. Lopez-Lucendo, D. Solis, S. Andre, J. Hirabayashi, K. Kasai, H. Kaltner, H. J. Gabius and A. Romero, *J. Mol. Biol.*, 2004, **343**, 957–970.

33 C. F. Bian, Y. Zhang, H. Sun, D. F. Li and D. C. Wang, *PLoS One*, 2011, **6**, e25007–e25016.

34 O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455–461.